Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

COUNCIL ON DRUGS

COUNCIL ON DRUGS NEW AND DRUGS NONOFFICIAL The based available evidence do in are on and not case descriptions of drugs following any endorsement the Council. imply by H. D. Kautz, M.D., Secretary. Ferrocholinate cho- available clinical The (Chel-Iron, Ferrolip).—Iron evidence, although meager, line citrate chelate.—A chelate bear the results of the labora¬ would to out prepared by reacting appear of ferric that ferrocholinate equimolar precipitated tory is, quantities freshly toxicity experiments; with choline citrate. The better tolerated in the seems to be hydroxide therapeutic dihydrogen structural formula of ferrocholinate than ferrous sulfate ferrous be are and may dosage repre¬ range sented follows: In the of so far as small number gluconate. patients mild were limited to observed, nausea, complaints or These tended <ÇH3)3 diarrhea, complaints constipation. CHzCO NCH2CH2OH to continuation and in on of no disappear therapy, case were so severe as to discontinu¬ they require HOC-CO. ance of medication. (OH) ,Ve On the basis of clinical these and laboratory HiC-CO' ferrocholinate have observations, an 0 may advantage over other iron administered orally preparations Actions Uses.—Ferrocholinate hematinic and is a from tolerance and of the of standpoint danger which is used for the iron treatment of de¬ agent acute after clinical http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

COUNCIL ON DRUGS

JAMA , Volume 171 (7) – Oct 17, 1959

Loading next page...
 
/lp/american-medical-association/council-on-drugs-K7cFs0CeCs
Publisher
American Medical Association
Copyright
Copyright © 1959 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1959.03010250029007
Publisher site
See Article on Publisher Site

Abstract

NEW AND DRUGS NONOFFICIAL The based available evidence do in are on and not case descriptions of drugs following any endorsement the Council. imply by H. D. Kautz, M.D., Secretary. Ferrocholinate cho- available clinical The (Chel-Iron, Ferrolip).—Iron evidence, although meager, line citrate chelate.—A chelate bear the results of the labora¬ would to out prepared by reacting appear of ferric that ferrocholinate equimolar precipitated tory is, quantities freshly toxicity experiments; with choline citrate. The better tolerated in the seems to be hydroxide therapeutic dihydrogen structural formula of ferrocholinate than ferrous sulfate ferrous be are and may dosage repre¬ range sented follows: In the of so far as small number gluconate. patients mild were limited to observed, nausea, complaints or These tended <ÇH3)3 diarrhea, complaints constipation. CHzCO NCH2CH2OH to continuation and in on of no disappear therapy, case were so severe as to discontinu¬ they require HOC-CO. ance of medication. (OH) ,Ve On the basis of clinical these and laboratory HiC-CO' ferrocholinate have observations, an 0 may advantage over other iron administered orally preparations Actions Uses.—Ferrocholinate hematinic and is a from tolerance and of the of standpoint danger which is used for the iron treatment of de¬ agent acute after clinical

Journal

JAMAAmerican Medical Association

Published: Oct 17, 1959

There are no references for this article.